ORIC Stock Analysis: Buy, Sell, or Hold?
ORIC - Oric Pharmaceuticals, Inc. Common Stock
$7.48
-5.20 (-41.00%)
▼
5d:
-36.11%
30d:
-44.67%
90d:
-7.49%
WAIT
LOW Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 04, 2026
Smart Money Accumulation
ORIC is down 7.5% this week, but smart money is accumulating calls. Top strike: $13 2026-05-15 with 167 OI. Call ratio: 95% View Scanner →
Strength: 8.3/10
Get Alerted When ORIC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ORIC is down 36.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ORIC is down 36.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ORIC is currently trading at $7.47, which is considered oversold relative to its 30-day fair value range of $10.93 to $13.54.
Technical Outlook: Technically, ORIC is in a uptrend. The price is currently testing key support at $8.80. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 41.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $21.23 (+184.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ORIC is in a uptrend. The price is currently testing key support at $8.80. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 41.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $21.23 (+184.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$10.93 -
$13.54
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-41.0%)
- BULLISH: Trading 184.0% below Wall St target ($21.23)
- WARNING: Recommendation downgraded due to -36.1% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$10.93 -
$13.54
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$8.80
Resistance Level
$13.04
Current Trend
Uptrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.77
Wall Street Target
$21.23
(+184.0%)
Share & Embed Analysis
Last updated: April 02, 2026 6:03 AM ET
Data refreshes hourly during market hours. Next update: 7:03 AM
Data refreshes hourly during market hours. Next update: 7:03 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ORIC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Dominic Piscitelli
SELL
52000 shares
2026-02-24
Dominic Piscitelli
SELL
10720 shares
2025-12-16
Jacob Chacko
SELL
33374 shares
2025-12-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1018 | 55 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 52 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 59 HOLD |
